Background
 Cytomegalovirus (CMV) is the most common and single most important viral infection in immunocompromised patients who undergo SOT (Solid Organ Transplant) or HSCT (Hematopoietic Stem Cell Transplant).  CMV infection usually develops during the first few months after transplantation, and is associated with clinical infectious diseases.  Direct effects of CMV disease include typical symptoms of clinical infectious diseases (i.e. fever, pneumonia, gastrointestinal ulcers and hepatitis). CMV infection can also disseminate to lungs, liver, pancreas, kidneys, stomach, intestine, brain, and parathyroid glands, and can be fatal.  Indirect effects of CMV correspond to the development of bacterial and fungal infections and/or acute or chronic graft rejection.  It is estimated that about 50-70 % of all transplant recipients have latent CMV infection, and that the incidence of clinically apparent CMV disease may affect from 20% to 60% of transplant patients.
Objective
To evaluate the impact of CMV disease on mortality, transplant rejections, hospital length of stay, hospitalisation costs and on some transplantation-related complications following solid organ transplantations (SOT) and stem cell transplantations (SCT).
Methods
 We conducted a retrospective cohort study of a database of hospitalisations in France (PMSI). Available data included demographics, hospital characteristics, diagnoses, healthcare procedures, length of stay, discharge status and costs for all hospitalisations that occurred in France in 2007.  Logistic regression was used to estimate the impact of CMV disease during initial hospitalisation on the probability of graft rejection, all-cause mortality and two transplantrelated complications during initial stay or following readmission.  The impact of CMV disease on costs was estimated using generalised linear modelling.  Separate analysis was conducted for SCT and SOT patients.  All estimates were adjusted on age, gender, transplant type, and several comorbidites. 
CONCLUSIONS
 CMV disease is associated with substantial increases in probability of graft rejection, all-cause mortality, hospital length of stay, hospitalisation costs and transplantation-related complications in French transplant recipients.  The burden associated with CMV disease is greater in SCT patients, compared to SOT patients  The costs and serious adverse events of antiviral therapy for CMV prophylaxis or pre-emption add to this burden, although it is not taken into account in this analysis  Further research is needed to take into account potential additional confounding factors in the estimates of the effect of CMV disease on the length of hospital stay and total hospital costs 
Results
 CMV disease incidence -Among 4,078 SOT recipients and 3,530 HSCT recipients, CMV disease was reported during initial stay in 65 (1.59%) and 65 (1.84%) patients respectively. Including all hospital stays, CMV disease was recorded in 298 (7.31%) SOT patients, and in 201 (5.69%) SCT patients -The risk of CMV disease during initial hospital stay was greatest for allogenic HSCT patients, at 5.67%. When subsequent hospitalisations are also considered, allogenic HSCT patients also have the greatest risk of developing CMV disease (at 16.65%) -The majority of heart transplant patients who develop CMV disease do it during their initial stay (i.e., 15 out of 22 patients), while the majority of other transplant patients, develop CMV disease at a later point.  All-cause mortality -Case fatality rates for all hospital stays were 6.74% and 8.87% in the SOT and HSCT recipients.
-For SCT (but not SOT) patients, there was also statistically significant difference between survival curves, by CMV status: Log-rank test : chi2(1) = 8.95; Pr=0.003  In multivariate analysis, CMV disease at initial stay was also associated with an increased mortality following HSCT at initial stay (odds ratio = 2.98, p=0.08), but not following SOT (OR=1.14, p=0.77).
-In multivariate analysis, CMV at initial stay is also strongly related to greater odds of transplant rejection. The size of association is bigger among SCT patients: -These results were further confirmed in Cox proportional hazard model analysis, which adjusts for data censoring when the outcome was mortality at any stay:  Graft rejection -Graft rejection at any stay was recorded for 21.6% of SOT recipients and in 3.17% of SCT recipients.
-Graft survival curves were statistically different for patients with and without CMV disease at initial hospital stay, both for SCT (log-rank chi2=24.4, p<0.001) and SOT patients (chi2=4.8, P=0.03):  Other transplantation-related complications -CMV was also associated with two complications in multivariate analysis, especially for SCT patients:  Length of stay -CMV disease at initial stay is related to longer hospital stay. The size of the association is stronger for SCT patients, for whom CMV disease during initial stay is associated with an increase in cumulative length of stay by 50.47 days (including all hospital stays). -However, these results should be interpreted with caution: patients who stay longer in hospital may have a greater chance of being diagnosed with CMV during their stay (thus the estimate may be overestimated)  Hospitalisation costs -To correct for potential non-linearities, GLM model with gamma family and log link was used -Average total hospitalisation costs (for all stays combined for 1 person in 2007) were €57,006 for HSCT and €43,898 for SOT patients. CMV disease was associated with increases in costs (relative to the average) by 97% (p<0.0001) for HSCT and 86.4% (p<0.0001) for SOT patients. -Patients who stay longer in hospital may have both greater costs and greater probability of being diagnosed with CMV while in hospital. We can therefore not exclude an overestimation of these costs. 
